DBV Technologies reported $58.5M in Current Liabilities for its fiscal quarter ending in September of 2026.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 332.22M 29.22M Sep/2026
Alnylam Pharmaceuticals USD 2.06B 550.49M Sep/2026
Amarin USD 175.14M 10.94M Sep/2026
BioCryst Pharmaceuticals USD 195.83M 13.02M Sep/2026
BioMarin Pharmaceutical USD 1.6B 59.17M Sep/2026
DBV Technologies USD 58.5M 4.2M Sep/2026
Galectin Therapeutics USD 14.62M 1.98M Jun/2024
Halozyme Therapeutics USD 476.09M 131.65M Sep/2026
Incyte USD 1.44B 125.72M Sep/2026
Insmed USD 596.57M 157.83M Sep/2026
Ionis Pharmaceuticals USD 435.29M 119.65M Sep/2026
Neurocrine Biosciences USD 984.6M 110.1M Sep/2026
PTC Therapeutics USD 776.08M 5.01M Sep/2026
Sarepta Therapeutics USD 656.35M 153.44M Sep/2026
Ultragenyx Pharmaceutical USD 389M 38M Sep/2026
United Therapeutics USD 624.3M 16.5M Sep/2026